Table of Contents

1 Study Coverage

• 1.1 Engineered T Cells Product
• 1.2 Market Segments
• 1.3 Key Manufacturers Covered
• 1.4 Market by Type
  • 1.4.1 Global Engineered T Cells Market Size Growth Rate by Product
  • 1.4.2 Tumor Infiltrating Lymphocytes
  • 1.4.3 T Cell Receptor {TCR}
  • 1.4.4 Chimeric Antigen Receptor (CAR)
• 1.5 Market by End User
  • 1.5.1 Global Engineered T Cells Market Size Growth Rate by End User
  • 1.5.2 Hospitals
  • 1.5.3 Cancer Research Centers
  • 1.5.4 Clinics
• 1.6 Study Objectives
• 1.7 Years Considered

2 Executive Summary

• 2.1 Global Engineered T Cells Market Size
  • 2.1.1 Global Engineered T Cells Revenue 2014-2025
  • 2.1.2 Global Engineered T Cells Sales 2014-2025
• 2.2 Engineered T Cells Growth Rate by Regions
  • 2.2.1 Global Engineered T Cells Sales by Regions
  • 2.2.2 Global Engineered T Cells Revenue by Regions

3 Breakdown Data by Manufacturers

• 3.1 Engineered T Cells Sales by Manufacturers
  • 3.1.1 Engineered T Cells Sales by Manufacturers
  • 3.1.2 Engineered T Cells Sales Market Share by Manufacturers
  • 3.1.3 Global Engineered T Cells Market Concentration Ratio (CR5 and HHI)
• 3.2 Engineered T Cells Revenue by Manufacturers
  • 3.2.1 Engineered T Cells Revenue by Manufacturers (2014-2019)
  • 3.2.2 Engineered T Cells Revenue Share by Manufacturers (2014-2019)
• 3.3 Engineered T Cells Price by Manufacturers
• 3.4 Engineered T Cells Manufacturing Base Distribution, Product Types
  • 3.4.1 Engineered T Cells Manufacturers Manufacturing Base Distribution, Headquarters
  • 3.4.2 Manufacturers Engineered T Cells Product Type
  • 3.4.3 Date of International Manufacturers Enter into Engineered T Cells Market
• 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Product

• 4.1 Global Engineered T Cells Sales by Product
• 4.2 Global Engineered T Cells Revenue by Product
• 4.3 Engineered T Cells Price by Product

5 Breakdown Data by End User

• 5.1 Overview
• 5.2 Global Engineered T Cells Breakdown Data by End User

6 North America

• 6.1 North America Engineered T Cells by Countries
  • 6.1.1 North America Engineered T Cells Sales by Countries
  • 6.1.2 North America Engineered T Cells Revenue by Countries
  • 6.1.3 United States
  • 6.1.4 Canada
  • 6.1.5 Mexico
• 6.2 North America Engineered T Cells by Product
• 6.3 North America Engineered T Cells by End User

7 Europe

• 7.1 Europe Engineered T Cells by Countries
  • 7.1.1 Europe Engineered T Cells Sales by Countries
  • 7.1.2 Europe Engineered T Cells Revenue by Countries
  • 7.1.3 Germany
  • 7.1.4 France
  • 7.1.5 UK
  • 7.1.6 Italy
  • 7.1.7 Russia
• 7.2 Europe Engineered T Cells by Product
• 7.3 Europe Engineered T Cells by End User

8 Asia Pacific

• 8.1 Asia Pacific Engineered T Cells by Countries
  • 8.1.1 Asia Pacific Engineered T Cells Sales by Countries
  • 8.1.2 Asia Pacific Engineered T Cells Revenue by Countries
  • 8.1.3 China
  • 8.1.4 Japan
  • 8.1.5 Korea
  • 8.1.6 India
  • 8.1.7 Australia
  • 8.1.8 Indonesia
  • 8.1.9 Malaysia
  • 8.1.10 Philippines
  • 8.1.11 Thailand
  • 8.1.12 Vietnam
  • 8.1.13 Singapore
• 8.2 Asia Pacific Engineered T Cells by Product
• 8.3 Asia Pacific Engineered T Cells by End User

9 Central & South America

• 9.1 Central & South America Engineered T Cells by Countries
  • 9.1.1 Central & South America Engineered T Cells Sales by Countries
  • 9.1.2 Central & South America Engineered T Cells Revenue by Countries
  • 9.1.3 Brazil
• 9.2 Central & South America Engineered T Cells by Product
• 9.3 Central & South America Engineered T Cells by End User

10 Middle East and Africa

• 10.1 Middle East and Africa Engineered T Cells by Countries
  • 10.1.1 Middle East and Africa Engineered T Cells Sales by Countries
  • 10.1.2 Middle East and Africa Engineered T Cells Revenue by Countries
  • 10.1.3 GCC Countries
  • 10.1.4 Turkey
  • 10.1.5 Egypt
  • 10.1.6 South Africa
• 10.2 Middle East and Africa Engineered T Cells by Product
• 10.3 Middle East and Africa Engineered T Cells by End User

11 Company Profiles

• 11.1 Autolus Limited
  • 11.1.1 Autolus Limited Company Details
  • 11.1.2 Company Business Overview
  • 11.1.3 Autolus Limited Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.1.4 Autolus Limited Engineered T Cells Products Offered
  • 11.1.5 Autolus Limited Recent Development
• 11.2 Bellicum Pharmaceuticals
  • 11.2.1 Bellicum Pharmaceuticals Company Details
  • 11.2.2 Company Business Overview
  • 11.2.3 Bellicum Pharmaceuticals Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.2.4 Bellicum Pharmaceuticals Engineered T Cells Products Offered
  • 11.2.5 Bellicum Pharmaceuticals Recent Development
• 11.3 Cells Medica
  • 11.3.1 Cells Medica Company Details
  • 11.3.2 Company Business Overview
  • 11.3.3 Cells Medica Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.3.4 Cells Medica Engineered T Cells Products Offered
  • 11.3.5 Cells Medica Recent Development
• 11.4 Elli Lilly and Company
  • 11.4.1 Elli Lilly and Company Company Details
  • 11.4.2 Company Business Overview
  • 11.4.3 Elli Lilly and Company Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.4.4 Elli Lilly and Company Engineered T Cells Products Offered
  • 11.4.5 Elli Lilly and Company Recent Development
• 11.5 Gilead Sciences
  • 11.5.1 Gilead Sciences Company Details
  • 11.5.2 Company Business Overview
  • 11.5.3 Gilead Sciences Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.5.4 Gilead Sciences Engineered T Cells Products Offered
  • 11.5.5 Gilead Sciences Recent Development
• 11.6 Juno Therapeutics
  • 11.6.1 Juno Therapeutics Company Details
  • 11.6.2 Company Business Overview
  • 11.6.3 Juno Therapeutics Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.6.4 Juno Therapeutics Engineered T Cells Products Offered
  • 11.6.5 Juno Therapeutics Recent Development
• 11.7 Novartis
  • 11.7.1 Novartis Company Details
  • 11.7.2 Company Business Overview
  • 11.7.3 Novartis Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.7.4 Novartis Engineered T Cells Products Offered
  • 11.7.5 Novartis Recent Development
• 11.8 Oxford Biomedica
  • 11.8.1 Oxford Biomedica Company Details
  • 11.8.2 Company Business Overview
  • 11.8.3 Oxford Biomedica Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.8.4 Oxford Biomedica Engineered T Cells Products Offered
  • 11.8.5 Oxford Biomedica Recent Development
• 11.9 Pfizer
  • 11.9.1 Pfizer Company Details
  • 11.9.2 Company Business Overview
  • 11.9.3 Pfizer Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.9.4 Pfizer Engineered T Cells Products Offered
  • 11.9.5 Pfizer Recent Development
• 11.10 Precision Bioscience
  • 11.10.1 Precision Bioscience Company Details
  • 11.10.2 Company Business Overview
  • 11.10.3 Precision Bioscience Engineered T Cells Sales, Revenue and Gross Margin (2014-2019)
  • 11.10.4 Precision Bioscience Engineered T Cells Products Offered
  • 11.10.5 Precision Bioscience Recent Development
• 11.11 Redmile Group
• 11.12 Seeking Alpha
• 11.13 Unum Therapeutics

12 Future Forecast

• 12.1 Engineered T Cells Market Forecast by Regions
  • 12.1.1 Global Engineered T Cells Sales Forecast by Regions 2019-2025
  • 12.1.2 Global Engineered T Cells Revenue Forecast by Regions 2019-2025
• 12.2 Engineered T Cells Market Forecast by Product
  • 12.2.1 Global Engineered T Cells Sales Forecast by Product 2019-2025
  • 12.2.2 Global Engineered T Cells Revenue Forecast by Product 2019-2025
• 12.3 Engineered T Cells Market Forecast by End User
• 12.4 North America Engineered T Cells Forecast
• 12.5 Europe Engineered T Cells Forecast
• 12.6 Asia Pacific Engineered T Cells Forecast
• 12.7 Central & South America Engineered T Cells Forecast
• 12.8 Middle East and Africa Engineered T Cells Forecast

13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

• 13.1 Market Opportunities and Drivers
• 13.2 Market Challenges
• 13.3 Market Risks/Restraints
• 13.4 Macroscopic Indicators

14 Value Chain and Sales Channels Analysis

• 14.1 Value Chain Analysis
• 14.2 Engineered T Cells Customers
• 14.3 Sales Channels Analysis
  • 14.3.1 Sales Channels
  • 14.3.2 Distributors

15 Research Findings and Conclusion

16 Appendix

• 16.1 Research Methodology
  • 16.1.1 Methodology/Research Approach
  • 16.1.2 Data Source
• 16.2 Author Details

The global Engineered T Cells market is valued at million US$ in 2018 and will reach million US$ by the end of 2025, growing at a CAGR of during 2019-2025. The objectives of this study are to define, segment, and project the size of the Engineered T Cells market based on company, product type, end user and key regions.

This report studies the global market size of Engineered T Cells in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Engineered T Cells in these regions.
This research report categorizes the global Engineered T Cells market by top players/brands, region, type and end user. This report also studies the global Engineered T Cells market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

The following manufacturers are covered in this report, with sales, revenue, market share for each company:
Autolus Limited
Bellicum Pharmaceuticals
Cells Medica
Elli Lilly and Company
Gilead Sciences
Juno Therapeutics
Novartis
Oxford Biomedica
Pfizer
Precision Bioscience
Redmile Group
Seeking Alpha
Unum Therapeutics

Market size by Product
Tumor Infiltrating Lymphocytes
T Cell Receptor {TCR}
Chimeric Antigen Receptor (CAR)
Market size by End User
Hospitals
Cancer Research Centers
Clinics

Market size by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
India
Japan
South Korea
Australia
Indonesia
Singapore
Malaysia
Philippines
Thailand
Vietnam
Europe
Germany
France
UK
Italy
Spain
Russia
Central & South America
Brazil
Rest of Central & South America
Middle East & Africa
GCC Countries
Turkey
Egypt
South Africa

The study objectives of this report are:
To study and analyze the global Engineered T Cells market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
To understand the structure of Engineered T Cells market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
Focuses on the key global Engineered T Cells companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
To project the value and sales volume of Engineered T Cells submarkets, with respect to key regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Engineered T Cells are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025

This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Engineered T Cells market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.